Abstract
The hepatitis C virus (HCV) non-structural 5A (NS5A) protein is essential for viral RNA replication and may play a role in subverting host intracellular signaling pathways. Although no intrinsic enzymatic activity has been ascribed to NS5A, this proline-rich hydrophilic phosphoprotein is likely to exert its functions by interacting with viral and cellular factors. Recent studies using the HCV replicon cell culture system as a model for HCV RNA replication as well as for high-throughput screening of pharmacological inhibitors have revealed blockade of NS5A as a promising therapeutic strategy for the treatment of HCV. This review will summarize our progress in understanding the role of NS5A in HCV RNA replication and will introduce the most recent patents on inhibitors of NS5A.
Keywords: HCV, NS5A, antivirals, HCV inhibitors, hyperphosphorylation
Recent Patents on Anti-Infective Drug Discovery
Title: NS5A - From Obscurity to New Target for HCV Therapy
Volume: 3 Issue: 2
Author(s): Uli Schmitz and Seng-Lai Tan
Affiliation:
Keywords: HCV, NS5A, antivirals, HCV inhibitors, hyperphosphorylation
Abstract: The hepatitis C virus (HCV) non-structural 5A (NS5A) protein is essential for viral RNA replication and may play a role in subverting host intracellular signaling pathways. Although no intrinsic enzymatic activity has been ascribed to NS5A, this proline-rich hydrophilic phosphoprotein is likely to exert its functions by interacting with viral and cellular factors. Recent studies using the HCV replicon cell culture system as a model for HCV RNA replication as well as for high-throughput screening of pharmacological inhibitors have revealed blockade of NS5A as a promising therapeutic strategy for the treatment of HCV. This review will summarize our progress in understanding the role of NS5A in HCV RNA replication and will introduce the most recent patents on inhibitors of NS5A.
Export Options
About this article
Cite this article as:
Schmitz Uli and Tan Seng-Lai, NS5A - From Obscurity to New Target for HCV Therapy, Recent Patents on Anti-Infective Drug Discovery 2008; 3 (2) . https://dx.doi.org/10.2174/157489108784746597
DOI https://dx.doi.org/10.2174/157489108784746597 |
Print ISSN 1574-891X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4071 |
Related Articles
-
NF-κB Links Keratinocytes and Lymphocytes in the Pathogenesis of Psoriasis
Recent Patents on Inflammation & Allergy Drug Discovery Protein Aggregation in Neurodegenerative Diseases: Insights from Computational Analyses
Current Bioinformatics Application of Glutathione as Anti-Oxidative and Anti-Aging Drugs
Current Drug Metabolism Prostate Cancer Gene Expression Marker 1 (PCGEM1): A Patented Prostate- Specific Non-Coding Gene and Regulator of Prostate Cancer Progression
Recent Patents on DNA & Gene Sequences Regulation of p53 Activity
Current Chemical Biology The Formulation of Lipid-Based Nanotechnologies for the Delivery of Fixed Dose Anticancer Drug Combinations
Current Drug Delivery Nanostructural Hybrid Sensitizers for Photodynamic Therapy
Current Pharmaceutical Design Emerging Role of Mucins in Epithelial to Mesenchymal Transition
Current Cancer Drug Targets The Complexities of TGF-β Action During Mammary and Squamous Cell Carcinogenesis
Current Pharmaceutical Biotechnology UGT1A1 Mediated Drug Interactions and its Clinical Relevance
Current Drug Metabolism A Nuclear Receptor-Mediated Xenobiotic Response and Its Implication in Drug Metabolism and Host Protection
Current Drug Metabolism Genus Euonymus: Chemical and Pharmacological Perception
Mini-Reviews in Organic Chemistry Genetically Engineered Stem Cells for Therapeutic Gene Delivery
Current Gene Therapy HPV as a Model for the Development of Prophylactic and Therapeutic Cancer Vaccines
Current Molecular Medicine Targeting Chemokine Receptor CXCR4 for Treatment of HIV-1 Infection, Tumor Progression, and Metastasis
Current Topics in Medicinal Chemistry Modulation of intracellular pH in human ovarian cancer.
Current Molecular Medicine Is the Epithelial-to-Mesenchymal Transition Clinically Relevant for the Cancer Patient?
Current Pharmaceutical Biotechnology Signal Transduction Abnormalities in Suicide: Focus on Phosphoinositide Signaling System
CNS & Neurological Disorders - Drug Targets Cross Talk between the Cardiovascular and Nervous Systems:Neurotrophic Effects of Vascular Endothelial Growth Factor (VEGF) and Angiogenic Effects of Nerve Growth Factor (NGF)-Implications in Drug Development
Current Pharmaceutical Design The Vitamin D/CYP24A1 Story in Cancer
Anti-Cancer Agents in Medicinal Chemistry